Related Experiment Video
Updated: Dec 16, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
Novel Nanocomplexes Targeting STAT3 Demonstrate Promising Anti-Ovarian Cancer Effects in vivo
Xiaolei Zhang1, Tao Lu1, Yanhui Ma1
1Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, People's Republic of China.
Background:
Cationic solid lipid nanoparticles (SLN) have attracted intensive interest as an effective gene delivery system for its high biocompatibility, stability and low cytotoxicity. In our previous study, we successfully prepared SLN-STAT3 decoy ODN complexes and made a primary study on its antitumor behavior in ovarian cancer cells in vitro. However, there is little information available so far about the effect of SLN-STAT3 decoy ODN complexes on ovarian cancer in vivo, either little information about the pharmacological toxicology in vivo.
Material And Methods:
We applied nanotechnology to improve the gene delivery system and synthesize SLN-STAT3 decoy ODN complexes. Xenograft mouse models were established to assess the antitumor effects of SLN-STAT3 decoy ODN on the tumor growth of ovarian cancer in vivo. To analyze the mechanisms of SLN-STAT3 decoy ODN, we investigated apoptosis, autophagy, epithelial-mesenchymal transition (EMT) in tumor tissues of nude mice and investigated the effects and toxicology of SLN-STAT3 decoy ODN complexes on the vital organs of nude mice.
Results:
The results showed that SLN-STAT3 decoy ODN complexes markedly inhibited tumor growth in vivo. SLN-STAT3 decoy ODN complexes could induce cell apoptosis through downregulating Bcl-2, survivin and pro caspase 3, but upregulating Bax and cleaved caspase 3. These complexes could also regulate autophagy through upregulating LC3A-II, LC3B-II and beclin-1, but downregulating p-Akt and p-mTOR. Moreover, these complexes could inhibit cancer cell invasion through reversing EMT. Besides, SLN-STAT3 decoy ODN complexes showed no obvious toxicity on vital organs and hematological parameters of nude mice.
Conclusion:
The molecular mechanisms that SLN-STAT3 decoy ODN complexes inhibit tumor growth involved activating the apoptotic cascade, regulating autophagy, and reversing EMT program; and these complexes showed no obvious toxicity on nude mice. Our study indicated that the nanocomplexes SLN-STAT3 decoy ODN might be a promising therapeutic approach for ovarian cancer treatment.
Insights
Solid lipid nanoparticles (SLN) carrying STAT3 decoy oligonucleotides (ODN) effectively inhibit ovarian cancer growth in vivo. These SLN-STAT3 decoy ODN complexes demonstrate low toxicity, suggesting promise for ovarian cancer therapy.
Area of Science:
- Nanotechnology
- Oncology
- Gene Delivery
Background:
- Cationic solid lipid nanoparticles (SLN) are explored for gene delivery due to biocompatibility and low cytotoxicity.
- Previous in vitro studies showed antitumor potential of SLN-STAT3 decoy ODN complexes in ovarian cancer cells.
- Limited in vivo data exists on the efficacy and toxicology of these complexes.
Purpose of the Study:
- To evaluate the in vivo antitumor efficacy of SLN-STAT3 decoy ODN complexes against ovarian cancer.
- To investigate the molecular mechanisms underlying the antitumor effects.
- To assess the in vivo pharmacological toxicology of the complexes.
Main Methods:
- Synthesis of SLN-STAT3 decoy ODN complexes using nanotechnology.
- Establishment of xenograft mouse models for in vivo efficacy assessment.
- Analysis of apoptosis, autophagy, epithelial-mesenchymal transition (EMT), and organ toxicology in tumor tissues and vital organs.
Main Results:
- SLN-STAT3 decoy ODN complexes significantly inhibited in vivo tumor growth.
- Complexes induced apoptosis, regulated autophagy, and reversed EMT.
- No significant toxicity was observed in vital organs or hematological parameters.
Conclusions:
- SLN-STAT3 decoy ODN complexes inhibit ovarian cancer growth by activating apoptosis, regulating autophagy, and reversing EMT.
- The complexes exhibit a favorable safety profile in vivo.
- SLN-STAT3 decoy ODN represents a promising therapeutic strategy for ovarian cancer.
More Related Videos
07:54Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting
Published on: March 25, 2019
07:59Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
Published on: December 5, 2020
